How to Test for Leaky Gut in 2026: What Actually Works

If you've asked your gastroenterologist to test you for leaky gut and been told there's no such test, they're not entirely wrong — but they're not entirely right either. There is no single clinically standardized test called a 'leaky gut test.' But there are multiple validated methods for measuring intestinal permeability, each with different mechanisms, accuracy profiles, costs, and clinical contexts. The problem is that most of these tests were developed for research settings and haven't made a clean transition to routine clinical practice. Meanwhile, a parallel ecosystem of commercial functional medicine labs offers permeability panels of varying validity, creating genuine confusion for patients who want answers. This guide provides a clear-eyed assessment of every available test for intestinal permeability in 2026 — what each measures, how accurate it is, what it costs, who uses it, and when it's actually worth pursuing versus simply starting an evidence-based gut healing protocol.

The Gold Standard: Lactulose/Mannitol Ratio Test

The lactulose/mannitol (or lactulose/rhamnose) urine ratio test is the most validated research tool for assessing intestinal permeability and remains the closest thing to a gold standard. The test works on a simple principle: two sugars are consumed — mannitol (a small molecule, ~182 Da) and lactulose (a large molecule, ~342 Da). Mannitol is readily absorbed transcellularly (through cells) by passive diffusion. Lactulose normally cannot pass through the tight junction seals between cells in a healthy gut. After consuming both sugars, urine is collected for 5-6 hours. The ratio of urinary lactulose to mannitol is calculated. A high ratio indicates that more lactulose is passing through than it should — meaning the paracellular barrier (tight junctions) is too porous. The test is used in research to quantify SIBO-related permeability, celiac disease activity, post-chemotherapy gut damage, and permeability changes from NSAID use. It's highly reproducible when performed under standardized conditions. Its limitations in clinical use include the need for precise patient preparation (no fermentable foods beforehand, standardized dosing), the fact that different labs use different reference ranges making cross-comparison difficult, and that it measures the entire small intestine as one zone — it can't localize where in the gut the permeability is occurring. Cost: varies widely; some university hospitals and specialized functional medicine labs offer this test for $150-400. It is rarely covered by insurance.

Zonulin Testing: Blood and Stool

Zonulin — the protein regulator of tight junction permeability discovered by Dr. Alessio Fasano — is commercially available as both a serum (blood) and stool assay. It's among the most ordered 'gut health' biomarkers in functional medicine practice. Unfortunately, there are significant caveats. The most widely used commercial zonulin ELISA kits have been shown in peer-reviewed studies to cross-react with complement proteins C3 and C4, as well as other haptoglobin-related proteins. This means a positive result may not reflect true zonulin (prehp2) levels at all. A 2019 study in PLOS ONE specifically demonstrated that two widely used commercial serum zonulin kits could not reliably detect actual zonulin protein. Stool zonulin tests (offered by labs including Genova Diagnostics and Diagnostic Solutions) are less studied but may more directly reflect intestinal production. However, stool zonulin hasn't been validated against the lactulose/mannitol gold standard in large cohorts, and pre-analytical variables (collection, transit time) affect results. Despite these limitations, zonulin testing remains useful as one data point in a broader clinical picture — particularly when the result is dramatically elevated and fits the overall clinical context. Cost: serum zonulin $80-150, stool zonulin (as part of comprehensive stool panel) $300-500. Rarely covered by insurance.

LPS Antibody Testing (IgA, IgG, IgM to Lipopolysaccharide)

Lipopolysaccharide (LPS) is a component of the outer membrane of gram-negative bacteria. In a healthy gut, LPS stays in the intestinal lumen. When gut permeability is increased, LPS translocates into the bloodstream, where the immune system generates antibodies against it. Testing for anti-LPS antibodies (IgA, IgG, IgM) is therefore an indirect marker of whether bacterial endotoxins have been crossing the gut barrier and triggering immune responses over time. This approach has some important advantages: the antibody response is cumulative and reflects sustained permeability over weeks to months (unlike the lactulose/mannitol test, which is a snapshot), and it directly measures the immune consequence of barrier dysfunction rather than just barrier function itself. Limitations include that elevated LPS antibodies could also reflect oral or systemic infection rather than gut permeability, and that some people produce more robust antibody responses than others, introducing individual variability. LPS antibody panels are offered by functional medicine labs (Cyrex Array 2 includes anti-LPS antibodies) and some research-oriented clinical labs. Cost: approximately $200-350 depending on the panel. Not typically covered by insurance.

Tight Junction Protein Antibodies: Occludin and Claudin

When the immune system identifies damaged tight junction proteins as foreign antigens — which can happen when the gut barrier is chronically disrupted — it may generate antibodies against occludin and claudin-3, the structural proteins that form tight junctions. Testing for these autoantibodies (most notably available through Cyrex Laboratories' Array 2) provides evidence not just that the barrier is porous, but that the immune system is actively targeting the integrity proteins themselves. Elevated occludin/claudin antibodies suggest a more chronic, immune-mediated disruption of gut barrier function rather than an acute, reversible permeability change. This distinction has treatment implications: an acute permeability state (from a GI infection, short antibiotic course, or single NSAID use) may resolve with barrier support, while an autoimmune attack on tight junction proteins may require a more targeted immunomodulatory approach. Cost: approximately $350-500 as part of the Cyrex Array 2 panel. Not covered by insurance.

Additional Permeability Markers: Citrulline, FABP2, and D-Lactate

Several additional biomarkers provide complementary information about gut barrier and intestinal cell health. Citrulline is an amino acid released by healthy small intestinal enterocytes. It serves as a functional marker of the intestinal absorptive surface — low serum citrulline indicates reduced villous surface area or enterocyte mass, as occurs in celiac disease, short bowel syndrome, or extensive mucosal damage. Normal citrulline levels suggest adequate functioning intestinal epithelium. Fatty acid binding protein 2 (FABP2, also called intestinal-FABP or I-FABP) is released from damaged enterocytes into circulation. It's a highly specific marker of acute intestinal epithelial injury. Elevated FABP2 in serum indicates active cell death in the intestinal lining. It's primarily used in research and critical care settings (mesenteric ischemia, NEC in premature infants) but is increasingly being explored as an intestinal injury biomarker. D-lactate is produced by bacterial fermentation of sugars. Humans produce only L-lactate, so elevated serum D-lactate is a fairly specific marker of bacteria fermenting in an environment that allows bacterial metabolites to cross into the bloodstream — suggesting both bacterial overgrowth and intestinal permeability. This is relevant to SIBO assessment. PEG (polyethylene glycol) probe testing is a research method using inert molecules of different sizes to map permeability across different intestinal segments. It's primarily used in academic research settings and not clinically available.

When Testing Is Worth It vs. Empirical Treatment

For most patients with suspected gut permeability, the honest answer is that testing is optional — not because the biology isn't real, but because the treatment plan rarely changes based on results. Whether your lactulose/mannitol ratio comes back borderline elevated or significantly elevated, the interventions are the same: treat underlying SIBO if present, remove gut-harming inputs (NSAIDs, alcohol, inflammatory foods), add gut-supportive nutrients (glutamine, zinc, vitamin D, collagen), and support the microbiome. Testing is worth pursuing when you want to establish a baseline for tracking treatment response over time, when your clinical picture is ambiguous and the test result will genuinely guide treatment decisions, when a diagnosis with established permeability associations (celiac disease, IBD, SIBO) needs objective confirmation, and when you're participating in a structured functional medicine program where panel results are used to calibrate the protocol. Testing is less worth pursuing when you're paying out of pocket for low-validity assays whose results won't change your treatment, when you're using a positive result to justify a supplement protocol that lacks independent evidence, or when the cost creates financial burden that would be better applied to validated treatment. For SIBO patients specifically: confirming and treating the bacterial overgrowth via breath test is a higher-yield first step than permeability testing. Effective SIBO treatment typically improves gut permeability as a secondary benefit.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.